Transdermal fentanyl for severe cancer-related pain

Palliative Medicine

Volumn 11, Issue 3, 1997, Pages 233-239

  Yeo, Winnie ^a   Lam, Kwok K ^a   Chan, Anthony T C ^a   Leung, Thomas W T ^a   Nip, Sau Y Wu ^a   Johnson, Philip J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Administration, cutaneous; Fentanyl; Neoplasms; Pain; Palliative care

Indexed keywords

FENTANYL; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; TRANSDERMAL DRUG ADMINISTRATION; VERTIGO;

EID: 0030983399     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1177/026921639701100308     Document Type: Article

References (17)

1. Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313: 84-95.
2. Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR. Absorption characteristics of transdermally administered fentanyl. Anaesthesiology 1989; 70: 928-34.
3. Buyse ME. Clinical trial methodology. In: Peckham M, Pinedo H, Veronesi U eds. Oxford textbook of oncology. Oxford: Oxford University Press, 1995; 2377-95.
4. Simmonds MA, Payne R, Richenbacher J, Moran K, Southam MA, Hershey MS. TTS (fentanyl) in the management of pain in patients with cancer. Proc Am Soc Clin Oncol 1989; 8: 324.
5. Slover R. Transdermal fentanyl: clinical trial at the University of Colorado Health Sciences Center. J Pain Symptom Manage 1992; 7(3): 45-47.
6. Korte W, Morant R. Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding - a pilot study in 20 patients. Support Care Cancer 1994; 2: 123-27.
7. Zech DFJ, Grond S, Lynch J, Stollenwerk B, Lehmann KA. Transdermal fentanyl and initial dose finding with patient-controlled analgesia in cancer pain. A pilot study of 20 terminally ill cancer patients. Pain 1992; 50: 293-301.
8. Gardner-Nix J, Hays H. A clinical evaluation of Duragaesic (transdermal fentanyl) for the treatment of chronic cancer pain. Proc Am Soc Clin Oncol 1995; 14: 176.
9. Payne R. Experience with transdermal fentanyl in advanced cancer pain. Eur J Pain 1990; 11: 98-101.
10. Sawe J, Dahlstrom VB, Paalzow L, Rane A. Morphine kinetics in cancer patients. Clin Pharmacol Ther 1981; 30: 629-35.
11. Lehmann KA. Patient-controlled intravenous analgesia for postoperative pain relief. Adv Pain Res Ther 1991; 18: 481-506.
12. Gourlay B, Kowalski SRE, Plummer JL, Cousins MJ, Armstrong PJ. Fentanyl blood concentration-analgesic response relationship in postoperative pain. Anaesth Analg 1988; 67: 329-37.
13. Miser AW, Narang PK, Dothage JA, Young RC, Sindelar W, Miser JS. Transdermal fentanyl for pain control in patients with cancer. Pain 1989; 27: 15-21.
14. Zech DFJ, Lehmann KA, Grond S. Transdermal (TTS) fentanyl in cancer pain management. Prog Palliat Care 1994; 2(2): 37-42.
15. Portenoy RK, Southam MA, Gupta SK, Lapin J, Layman M, Inturrisi CE, Foley KM. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anaesthesiology 1993; 78: 36-43.
16. Ahmedzai S, Allan E, Fallon M, Finlay IG, Hanks GW, Hanna M, Regnard CFB, Reilly C. Transdermal fentanyl in cancer pain. J Drug Dev 1994; 6: 93-97.
17. Slappendal R, Lako SJ, Crul BJP. Gastrointestinal side effects diminishes after switch over from morphine to transdermal fentanyl. Ann Oncol 1994; 5: 200.